U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C43H53NO14.3H2O
Molecular Weight 861.9251
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOCETAXEL

SMILES

O.O.O.[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6

InChI

InChIKey=XCDIRYDKECHIPE-QHEQPUDQSA-N
InChI=1S/C43H53NO14.3H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;;;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);3*1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;;;/m0.../s1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C43H53NO14
Molecular Weight 807.8792
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 11
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including

Docetaxel was protected by patents (U.S. patent and European patent) which were owned by Sanofi-Aventis, and so was available only under the Taxotere brand name internationally. The European patent expired in 2010. Docetaxel is a clinically well-established anti-mitotic chemotherapy medication used for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarcinoma and head and neck cancer. Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the β-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

CNS Activity

Curator's Comment: docetaxel cannot cross the blood–brain barrier and control metastatic foci

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TAXOTERE

Approved Use

INDICATIONS & USAGE Docetaxel injection concentrate is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Launch Date

8.3203201E11
Primary
TAXOTERE

Approved Use

INDICATIONS & USAGE Docetaxel injection concentrate is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Launch Date

8.3203201E11
Primary
TAXOTERE

Approved Use

INDICATIONS & USAGE Docetaxel injection concentrate is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Launch Date

8.3203201E11
Primary
TAXOTERE

Approved Use

INDICATIONS & USAGE Docetaxel injection concentrate is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Launch Date

8.3203201E11
Primary
TAXOTERE

Approved Use

INDICATIONS & USAGE Docetaxel injection concentrate is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Launch Date

8.3203201E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
742 nM
20 mg/m² 1 times / week multiple, intravenous
dose: 20 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3737 nM
100 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1284 nM × h
20 mg/m² 1 times / week multiple, intravenous
dose: 20 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5562 nM × h
100 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.99 h
20 mg/m² 1 times / week multiple, intravenous
dose: 20 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.74 h
100 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
11.1 h
100 mg/m² 1 times / hour multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
100 mg/m² 1 times / hour multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 75 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 75 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 51 years (range: 36 - 65 years)
n = 39
Health Status: unhealthy
Condition: advanced breast cancer:
Age Group: 51 years (range: 36 - 65 years)
Sex: F
Population Size: 39
Sources:
Disc. AE: Fluid retention...
AEs leading to
discontinuation/dose reduction:
Fluid retention (16 patients)
Sources:
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
DLT: Fatigue, Asthenia...
Other AEs: Nail toxicity, Alopecia...
Dose limiting toxicities:
Fatigue (grade 3-4, 2 patients)
Asthenia (grade 3-4, 2 patients)
Skin toxicity (grade 3-4, 1 patient)
Diarrhea (grade 3-4, 1 patient)
Other AEs:
Nail toxicity (grade 3-4, 1 patient)
Alopecia (grade 2, 1 patient)
Leukopenia (grade 3, 2 patients)
Sources:
52 mg/m2 1 times / week multiple, intravenous
Dose: 52 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 52 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 3
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 3
Sources:
DLT: Fatigue, Asthenia...
Dose limiting toxicities:
Fatigue (grade 3-4, 3 patients)
Asthenia (grade 3-4, 3 patients)
Sources:
150 mg/m2 single, intravenous
Overdose
Dose: 150 mg/m2
Route: intravenous
Route: single
Dose: 150 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Other AEs: Neutropenia, Asthenia...
Other AEs:
Neutropenia (severe)
Asthenia (mild)
Epidermal and dermal conditions
Paresthesia (mild)
Sources:
200 mg/m2 single, intravenous
Overdose
Dose: 200 mg/m2
Route: intravenous
Route: single
Dose: 200 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Other AEs: Neutropenia, Asthenia...
Other AEs:
Neutropenia (severe)
Asthenia (mild)
Epidermal and dermal conditions
Paresthesia (mild)
Sources:
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Disc. AE: Hypersensitivity...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity (severe)
Sources:
100 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Other AEs: Hepatotoxicity...
AEs

AEs

AESignificanceDosePopulation
Fluid retention 16 patients
Disc. AE
75 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 75 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 75 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 51 years (range: 36 - 65 years)
n = 39
Health Status: unhealthy
Condition: advanced breast cancer:
Age Group: 51 years (range: 36 - 65 years)
Sex: F
Population Size: 39
Sources:
Alopecia grade 2, 1 patient
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
Leukopenia grade 3, 2 patients
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
Nail toxicity grade 3-4, 1 patient
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
Diarrhea grade 3-4, 1 patient
DLT
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
Skin toxicity grade 3-4, 1 patient
DLT
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
Asthenia grade 3-4, 2 patients
DLT
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
Fatigue grade 3-4, 2 patients
DLT
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
Asthenia grade 3-4, 3 patients
DLT
52 mg/m2 1 times / week multiple, intravenous
Dose: 52 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 52 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 3
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 3
Sources:
Fatigue grade 3-4, 3 patients
DLT
52 mg/m2 1 times / week multiple, intravenous
Dose: 52 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 52 mg/m2, 1 times / week
Sources:
unhealthy, 58 years (range: 41-81 years)
n = 3
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 3
Sources:
Epidermal and dermal conditions
150 mg/m2 single, intravenous
Overdose
Dose: 150 mg/m2
Route: intravenous
Route: single
Dose: 150 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Asthenia mild
150 mg/m2 single, intravenous
Overdose
Dose: 150 mg/m2
Route: intravenous
Route: single
Dose: 150 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Paresthesia mild
150 mg/m2 single, intravenous
Overdose
Dose: 150 mg/m2
Route: intravenous
Route: single
Dose: 150 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Neutropenia severe
150 mg/m2 single, intravenous
Overdose
Dose: 150 mg/m2
Route: intravenous
Route: single
Dose: 150 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Epidermal and dermal conditions
200 mg/m2 single, intravenous
Overdose
Dose: 200 mg/m2
Route: intravenous
Route: single
Dose: 200 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Asthenia mild
200 mg/m2 single, intravenous
Overdose
Dose: 200 mg/m2
Route: intravenous
Route: single
Dose: 200 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Paresthesia mild
200 mg/m2 single, intravenous
Overdose
Dose: 200 mg/m2
Route: intravenous
Route: single
Dose: 200 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Neutropenia severe
200 mg/m2 single, intravenous
Overdose
Dose: 200 mg/m2
Route: intravenous
Route: single
Dose: 200 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Hypersensitivity severe
Disc. AE
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Hepatotoxicity grade 5
100 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, adult
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
likely
Comment: In vivo studies showed that the exposure o f docetaxel increased 2.2-fold when it was coadministered with ketoconazole, a potent inhibitor o f CYP3A4. Protease inhibitors, particularly ritonavir, may increase the exposure o f docetaxe
Page: 12.0
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: The effect o f ketoconazole (a strong CYP3A4 inhibitor) on the pharmacokinetics o f docetaxel was investigated in 7 cancer patients. Patients were randomized to receive either docetaxel (100 mg/m2 intravenous) alone or docetaxel (10 mg/m2 intravenous) in combination with ketoconazole (200 mg orally once daily for 3 days) in a crossover design with a 3-week washout period. The results o f this study indicated that the mean dose-normalized AUC o f docetaxel was increased 2.2-fold and its clearance was reduced by 49% when docetaxel was coadministration with ketoconazole
Page: 13.0
PubMed

PubMed

TitleDatePubMed
[The mechanism of docetaxel-induced apoptosis in human lung cancer cells].
2000 May
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
2001 Aug
Docetaxel induced cardiotoxicity.
2001 Aug
Reversible hepatic coma possibly induced by docetaxel treatment.
2001 Feb-Mar
Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
2001 Jan 15
Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
2001 Jan-Feb
Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
2001 Nov
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
2002
Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
2002 Feb
Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report.
2002 Nov-Dec
A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.
2002 Oct 15
Cystic maculopathy with normal capillary permeability secondary to docetaxel.
2003 Apr
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
2003 Feb
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
2003 Feb
Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid.
2003 Feb
Docetaxel-related skin, nail, and vascular toxicity.
2003 Jan
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
2003 Mar
Reversible life-threatening encephalopathy in the absence of hepatic failure following conventional doses of docetaxel.
2003 May
Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
2003 May-Jun
ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.
2003 Nov 10
Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
2004 Feb
All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells.
2004 Jan 15
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.
2004 Jun 14
Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel.
2004 Oct 8
Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs.
2004 Sep 10
Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.
2005
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.
2005 Dec
Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy.
2005 Feb
Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory.
2005 Jan
HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
2005 Jun 1
Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
2005 May-Jun
PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism.
2005 Oct 15
[Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere].
2005 Sep
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
2006 Apr
Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
2006 Aug 15
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
2006 Jun 5
Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model.
2006 Mar-Apr
Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB.
2006 May
Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
2006 Oct 1
Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
2007 Aug
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
2007 Aug
Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products.
2007 Aug
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
2007 Feb
Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway.
2007 Feb 15
Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells.
2007 Jan
Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3.
2007 Mar 8
Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
2007 May-Jun
Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
2007 Oct
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
2007 Sep 1
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
2008 Feb
Patents

Sample Use Guides

Breast Cancer: 60 mg/m2 to 100 mg/m2 administered intravenously over 1 hour every 3 weeks. Non-Small Cell Lung Cancer: 75 mg/m2 administered intravenously over 1 hour every 3 weeks. Prostate Cancer: 75 mg/m2 every 3 weeks as a 1 hour intravenous infusion. Gastric Adenocarcinoma: 75 mg/m2 as a 1 hour intravenous infusion, followed by cisplatin 75 mg/m2 , as a 1 to 3 hour intravenous infusion (both on day 1 only), followed by fluorouracil 750 mg/m2 per day given as a 24-hour continuous intravenous infusion for 5 days, starting at the end of the cisplatin infusion Head and Neck Cancer: Induction chemotherapy followed by radiotherapy: For the induction treatment of locally advanced inoperable SCCHN, the recommended dose of TAXOTERE (docetaxel) is 75 mg/m2 as a 1 hour intravenous infusion followed by cisplatin 75 mg/m2 intravenously over 1 hour, on day one, followed by fluorouracil as a continuous intravenous infusion at 750 mg/m2 per day for five days. This regimen is administered every 3 weeks for 4 cycles. Following chemotherapy, patients should receive radiotherapy.
Route of Administration: Intravenous
In Vitro Use Guide
The in vitro antiproliferative effect of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin was assessed in a range of human tumour types, including 25 tumour cell lines and 35 primary cultures. In all comparisons docetaxel and paclitaxel were much more potent than cisplatin with IC50 values of the taxoids being in the nanomolar range. Docetaxel generally was two- to four-fold more cytotoxic than paclitaxel. The sensitivity profile of the cell lines, which was based on the IC50 values, indicated a certain degree of cross-sensitivity between paclitaxel and docetaxel (linear regression analysis; r = 0.73, p < 0.001
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:26:50 UTC 2023
Edited
by admin
on Fri Dec 15 15:26:50 UTC 2023
Record UNII
15H5577CQD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOCETAXEL
EMA EPAR   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
TAXOTERE
Brand Name English
(2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate
Common Name English
DOCETAXEL (AS TRIHYDRATE)
Common Name English
DOCETAXEL [VANDF]
Common Name English
DOCETAXEL HYDRATE [JAN]
Common Name English
Docetaxel [WHO-DD]
Common Name English
RP 56976
Code English
DOCETAXEL [USP-RS]
Common Name English
DOCETAXEL [USAN]
Common Name English
DOCETAXEL TRIHYDRATE
EP   MI  
Common Name English
DOCETAXEL [USP MONOGRAPH]
Common Name English
DOCETAXEL [EMA EPAR]
Common Name English
DOCETAXEL [USP IMPURITY]
Common Name English
DOCETAXEL TRIHYDRATE [MI]
Common Name English
DOCETAXEL TRIHYDRATE [EP MONOGRAPH]
Common Name English
DOCETAXEL [EP MONOGRAPH]
Common Name English
XRP6976
Code English
RP-56976
Code English
DOCETAXEL [ORANGE BOOK]
Common Name English
DOCETAXEL HYDRATE
JAN  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67437
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
EMA ASSESSMENT REPORTS DOCEFREZ(WITHDRAWN: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
EMA ASSESSMENT REPORTS DOCETAXEL TEVA (AUTHORIZED: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
EMA ASSESSMENT REPORTS DOCETAXEL KABI (AUTHORIZED: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
EMA ASSESSMENT REPORTS TAXESPIRA (AUTHORISED: CARCINOMA, NON-SMALL-CELL LUNG)
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
LIVERTOX NBK548899
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
NDF-RT N0000175592
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
WHO-VATC QL01CD02
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
EMA ASSESSMENT REPORTS TAXOTERE (AUTHORIZED: STOMACH NEOPLASMS)
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
EMA ASSESSMENT REPORTS DOCETAXEL WINTHROP (AUTHORIZED: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
EMA ASSESSMENT REPORTS DOCETAXEL MYLAN (AUTHORIZED: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
EMA ASSESSMENT REPORTS DOCETAXEL TEVA PHARMA(AUTHORIZED: CARCINOMA, NON-SMALL-CELL LUNG)
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
EMA ASSESSMENT REPORTS DOCETAXEL ACCORD (AUTHORIZED: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
EMA ASSESSMENT REPORTS TAXOTERE (AUTHORIZED: BREAST, PROSTETIC, STOMACH, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
WHO-ATC L01CD02
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
FDA ORPHAN DRUG 649918
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
NCI_THESAURUS C1490
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
Code System Code Type Description
CHEBI
4672
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
EVMPD
SUB25446
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
MESH
C067311
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
USAN
FF-68
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
EPA CompTox
DTXSID80872444
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
MERCK INDEX
m4712
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY Merck Index
WIKIPEDIA
DOCETAXEL
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
PUBCHEM
148123
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
RS_ITEM_NUM
1224551
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
ChEMBL
CHEMBL92
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
RXCUI
72962
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY RxNorm
LACTMED
Docetaxel
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
IUPHAR
6809
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
CHEBI
59809
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
SMS_ID
100000089469
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
NCI_THESAURUS
C1526
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
DRUG CENTRAL
939
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
DAILYMED
15H5577CQD
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
CAS
148408-66-6
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
DRUG BANK
DB01248
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
FDA UNII
15H5577CQD
Created by admin on Fri Dec 15 15:26:50 UTC 2023 , Edited by admin on Fri Dec 15 15:26:50 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
ANHYDROUS->SOLVATE
TRANSPORTER -> SUBSTRATE
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC